Watch out Bris­tol My­ers, Mer­ck is right on your heels with more pos­i­tive Keytru­da da­ta to take to the FDA

Mer­ck an­nounced pos­i­tive Phase III re­sults to back yet an­oth­er in­di­ca­tion for cash cow Keytru­da — this time as a first-line esophageal can­cer treat­ment in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.